Monoclonal antibody therapeutics are highly targeted biological drugs that are generated from a single type of immune cell cloned to make identical antibody clones and used in targeted cancer treatment and other diseases. These antibodies bind to specific antigens on targeted cells or secreted molecules and interfere with their function.
The global monoclonal antibody therapeutics market Growth is estimated to be valued at US$ 205.39 billion in 2023 and is expected to exhibit a CAGR of 12.69% during the forecast period (2023-2030).
Key Takeaways
Key players operating in the monoclonal antibody therapeutics are copyright Inc., Novartis AG, Bayer AG, Sanofi, F. Hoffmann-La Roche Ltd, Eli Lilly and Company, Merck KGaA, GSK plc., AbbVie Inc., Bristol-Myers Squibb Company, Regeneron Pharmaceuticals Inc., AstraZeneca, AbCellera Biologics Inc., Molecular Depot LLC, DAIICHI SANKYO COMPANY, LIMITED., Abbott, Biogen, Thermo Fisher Scientific, Inc., Cell Signaling Technology, Inc, Intas Pharmaceuticals Ltd., Avantor Inc., UCB S.A., Merus N.V., GENEXTGENOMICS.COM, Biogenuix ., Bristol-Myers Squibb Company, Regeneron Pharmaceuticals, Amgen Inc, Johnson & Johnson, and Biogen Inc. Some key opportunities in the market include increasing prevalence of cancer and autoimmune diseases, growing demand for biosimilars, and focus on personalized medicine. Technological advancements such as bispecific monoclonal antibody therapy and advancements in engineering antibodies are fueling market growth.
Market drivers
One of the key drivers propelling the Monoclonal Antibody Therapeutics Market Growth is the increasing demand for targeted cancer therapy. Monoclonal antibodies have revolutionized cancer treatment by directing immune cells to cancer cells with high specificity. These antibodies have fewer side effects compared to conventional chemotherapy. They have demonstrated significant clinical benefits in several cancer types including breast cancer, colon cancer, lung cancer, lymphoma, and leukemia. Furthermore, the rising geriatric population which is highly susceptible to chronic diseases including cancer is boosting the demand.
Current challenges in the Monoclonal Antibody Therapeutics Market:
The development and production of monoclonal antibodies comes with considerable costs and infrastructure requirements. Designing clinical trials to demonstrate safety and efficacy of these therapies also requires substantial financial and time commitments. Ensuring availability and accessibility to such high-cost drugs remains a challenge worldwide. Other issues include developing antibodies against difficult disease targets, improving pharmacokinetic properties and resistance to immunogenicity.
SWOT Analysis
Strength: High specificity and purity of monoclonal antibodies makes them suitable for targeted delivery of cancer drugs with fewer side effects. They can also bind to disease markers with greater accuracy than conventional drugs.
Weakness: Developing monoclonal antibodies is an expensive, time-consuming and complex process. Manufacturing them at large scale requires dedicated facilities and bioprocess expertise.
Opportunity: Growing focus on precision medicine and biologics has increased investment for developing monoclonal antibodies in disease areas like immunology, oncology and infectious diseases. Biosimilars also provide opportunities to expand affordable access.
Threats: Patent expiries of blockbuster monoclonal antibody drugs will intensify competition from biosimilars. Increased development of cell and gene therapies poses a long-term threat for some monoclonal antibody indications.
Get More Insights On- Monoclonal Antibody Therapeutics Market
Get This Report In Japanese-
Get This Report In Korean-
About Author:
Alice Mutum is a seasoned senior content editor at Coherent Market Insights, leveraging extensive expertise gained from her previous role as a content writer. With seven years in content development, Alice masterfully employs SEO best practices and cutting-edge digital marketing strategies to craft high-ranking, impactful content. As an editor, she meticulously ensures flawless grammar and punctuation, precise data accuracy, and perfect alignment with audience needs in every research report. Alice's dedication to excellence and her strategic approach to content make her an invaluable asset in the world of market insights.
( LinkedIn: www.linkedin.com/in/alice-mutum-3b247b137 )
copyright src="chrome-extension://fpjppnhnpnknbenelmbnidjbolhandnf/content_script_web_accessible/ecp_regular.js" type="text/javascript">